FDA Approves Amgen’s Parsabiv (Etelcalcetide) for Secondary Hyperparathyroidism
Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with…
Read More...
Read More...